MS Virtual 2020

8th Joint ACTRIMS and ECTRIMS Meeting

No new safety signals in ofatumumab open-label data

Low-dose rituximab as effective as high-dose, but safer

Induction more effective than escalation as strategy in RRMS

Management of PPMS and SPMS with approved DMT

Amantadine, modafinil, and methylphenidate for MS-related fatigue

Predictive value of neurodegenerative CSF markers in MS

Masitinib possible new treatment of progressive MS

Gender-based approach to MS therapeutics: a missed opportunity

Eculizumab reduces long-term relapse risk in AQP4+ NMOSD

Cardiovascular risk factors linked to brain atrophy in younger MS patients

Gold nanocrystals may improve brain metabolic profile

Functional potential of gut microbiome in paediatric MS

MS patients have no increased risk of contracting COVID-19

EDSS and age are risk factors for severe COVID-19 in MS patients

Anti-CD20 mAbs associated with worse COVID-19 outcomes

Brain alterations at onset of first demyelinating event

Interrupting DMT due to pregnancy increases NfL levels in MS

NG-specific biomarkers can quickly differentiate NMOSD from MS

Top image: @ iStockPhoto: wildpixel

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.